Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and BioLineRx Ltd. (:), both competing one another are Biotechnology companies. We will compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ligand Pharmaceuticals Incorporated||238.78M||9.98||764.38M||5.64||21.77|
In table 1 we can see Ligand Pharmaceuticals Incorporated and BioLineRx Ltd.’s gross revenue, earnings per share and valuation.
Table 2 demonstrates the return on assets, net margins and return on equity of Ligand Pharmaceuticals Incorporated and BioLineRx Ltd.
|Net Margins||Return on Equity||Return on Assets|
|Ligand Pharmaceuticals Incorporated||320.12%||21.6%||8.9%|
The table given features the ratings and recommendations for Ligand Pharmaceuticals Incorporated and BioLineRx Ltd.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ligand Pharmaceuticals Incorporated||0||0||2||3.00|
Ligand Pharmaceuticals Incorporated’s average target price is $222, while its potential upside is 83.17%.
Insider and Institutional Ownership
Roughly 0% of Ligand Pharmaceuticals Incorporated shares are held by institutional investors while 26.75% of BioLineRx Ltd. are owned by institutional investors. Insiders held roughly 2.1% of Ligand Pharmaceuticals Incorporated’s shares. On the other hand, insiders held about 3.46% of BioLineRx Ltd.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ligand Pharmaceuticals Incorporated||-0.66%||3.89%||-24.58%||-52.2%||-20.61%||-9.59%|
For the past year BioLineRx Ltd. has weaker performance than Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated beats on 10 of the 11 factors BioLineRx Ltd.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.